Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$137.72 USD

137.72
562,365

+1.77 (1.30%)

Updated Jul 16, 2024 04:00 PM ET

After-Market: $137.80 +0.08 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

DaVita HealthCare (DVA) Rises Higher Than Market: Key Facts

by Zacks Equity Research

DaVita HealthCare (DVA) reachead $137.72 at the closing of the latest trading day, reflecting a +1.3% change compared to its last close.

DaVita (DVA) Gains 29.8% YTD: What's Driving the Stock?

by Zacks Equity Research

DaVita's (DVA) shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.

Patterson Companies (PDCO) Aims to Streamline Patient Experience

by Zacks Equity Research

Patterson Companies' (PDCO) latest integration features are likely to provide customers with additional options to streamline their experience.

Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results

by Zacks Equity Research

Terumo (TRUMY) subsidiary Microvention's SOFAST study validates the SOFIA Flow Plus Aspiration Catheter's speed, efficacy and safety in stroke thrombectomy.

Alcon (ALC) Rides on Innovation, Balanced Segmental Sales

by Zacks Equity Research

Alcon (ALC) is witnessing growth in its over-the-counter portfolio, mainly driven by favorable pricing and a sustained family of products.

Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis

by Zacks Equity Research

Enovis (ENOV) introduces the AltiVate Reverse Glenoid System, expanding the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates.

Reasons to Retain Veeva Systems (VEEV) in Your Portfolio Now

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock. However, data security threats and escalating costs are a concern.

Quest Diagnostics (DGX) Set to Acquire OhioHealth's Lab Services

by Zacks Equity Research

Quest Diagnostics' (DGX) new agreement is likely to help expand access to cost-effective and advanced laboratory services in Ohio.

3 Reasons Why You Should Hold McKesson (MCK) Stock for Now

by Zacks Equity Research

McKesson's (MCK) robust Biologics business raises optimism about the stock.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now

by Zacks Equity Research

Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

Roche Holding's (RHHBY) Accu-Chek SmartGuide Receives CE Mark

by Zacks Equity Research

Roche Holding (RHHBY) announces the receipt of CE Mark for its Accu-Chek SmartGuide CGM solution which is intended toward providing better diabetes management.

Philips (PHG) Gains Despite Recall of SENSE XL Torso Coils

by Zacks Equity Research

Philips (PHG) issues an urgent recall of SENSE XL Torso coils (1.5T and 3.0T) due to heating risks during MRI scans.

Here's Why You Should Add DaVita (DVA) to Your Portfolio

by Zacks Equity Research

DaVita's (DVA) strength in its kidney care raises optimism about the stock.

Masimo (MASI) Gets Non-Binding Offer for Consumer Business

by Zacks Equity Research

Masimo (MASI) gets an acquisition offer for its consumer business from an undisclosed entity. The deal is likely to close later in 2024.

GE HealthCare's (GEHC) New Solution to Aid Prostate Treatment

by Zacks Equity Research

GE HealthCare's (GEHC) MIM Software introduced the MIM Symphony HDR Prostate to provide direct tumor visualization using MRI images during live ultrasound procedures for HDR prostate treatments.

Here's Why You Should Retain Nevro (NVRO) Stock for Now

by Zacks Equity Research

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

Microbot Medical (MBOT) Progresses in Its Human Clinical Trial

by Zacks Equity Research

Microbot Medical's (MBOT) latest patient enrollment in its pivotal human clinical trial is expected to support the future submission to the FDA for the commercialization of the LIBERTY system.

IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint

by Zacks Equity Research

IceCure's (ICCM) ProSense cryoablation system demonstrated a 100% complete ablation rate for breast cancer per a study published in "Cancers."

Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.

3 Reasons Why You Should Hold Avantor (AVTR) Stock for Now

by Zacks Equity Research

Avantor's (AVTR) strong product portfolio raises optimism about the stock.

Orthofix Medical's (OFIX) Fitbone System Gets FDA Clearance

by Zacks Equity Research

Orthofix Medical (OFIX) announces the FDA clearance and first U.S. implant of the Fitbone Transport and Lengthening System, used to treat large bone defects in the femur and tibia.

Masimo (MASI) Preliminary Q2 Results Aided by Healthcare Unit

by Zacks Equity Research

Masimo's (MASI) second-quarter 2024 results are likely to reflect the strength in the Healthcare business.

Inspire Medical (INSP) Dips on FDA Recall of IPG Model 3028

by Zacks Equity Research

The recall of Inspire Medical 's (INSP) Inspire IV Implantable Pulse Generators might dampen the company's future sales.

Here's Why DaVita HealthCare (DVA) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

DaVita HealthCare (DVA) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

DaVita HealthCare (DVA) concluded the recent trading session at $137.92, signifying a +0.39% move from its prior day's close.